HeartBeam (Nasdaq:BEAT) announced today that it made significant developments in the AI applied to its proprietary ECG technology.
Santa Clara, California-based HeartBeam develops its proprietary vectorelectrocardiography (VECG) technology. The company aims to provide diagnostic and prognostic insights about cardiac health beyond what standard 12-lead ECGs provide.
HeartBeam’s VECG technology collects 3D signals of the heart and converts them into an easy-to-interpret 12-lead ECG. The company designed it for use with portable, patient-friendly devices. Its first planned application comes in the form of the AIMIGo credit card-sized device.
The company leverages AI to analyze data-rich signals captured by the VECG, hoping to improve diagnostic accuracy and extract unique information. That includes complex heart rhythms, subtle signs of deteriorating health and potentially missed cardiac events.
According to a news release, the data collected could eventually help create a comprehensive repository. This repository could unlock personalized AI-driven insights to improve cardiac care.
HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
“It’s rare to acquire a large series of 12-lead ECGs from the same individual over time,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “By pioneering a user-friendly device that enables frequent 12-lead ECGs over time and by coupling AI with our proprietary VECG technology that can go beyond a 12-lead ECG, HeartBeam is well-positioned to identify nuanced cardiac trends that could ultimately improve patient care.”
HeartBeam makes new appointments to support AI endeavor
To lead its AI effort, HeartBeam named Mohammad Shokoohi-Yekta as senior director of machine learning. Shokoohi-Yekta most recently worked at Microsoft, where he spearheaded a range of efforts to improve the accuracy of software tools. That includes the use of advanced analytics, machine learning techniques and predictive modeling.
Additionally, HeartBeam said he played a pivotal role in growing a small team of data scientists and AI professionals into an influential part of Microsoft. He also previously held data science and machine learning positions at Apple.
In another appointment to support this effort, the company named Lance Myers as chief AI advisor. He previously served as head of cardiovascular devices and head of data science at Verily Life Sciences. There, Myers led a team developing a novel heart failure monitoring solution.
Previously, Myers held leadership roles at Sentrian, VivoSense, Boston Neurosciences and Vivometrics. He currently serves as a board member for VivoSense.
“Having Mohammad and Lance join the company will be invaluable as we work towards our mission of transforming cardiac health,” Vajdic said. “With their expertise and acumen, I am confident both will make an immediate impact to harness the power of AI within our data-rich VECG technology to ensure we deliver the most impactful technology with the goal of improving patient outcomes.”
